LearnGlossaryMarketStocksSuperinvestorsSign in

VSTM

Verastem, Inc.

Healthcare · $707M market cap

Verdict

We can't put a fair value on VSTM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-27.6% a year✗
Sales growth-10.5% a year✗
Free cash flow growth—?
Return on invested capital-89.8%✗

Follow VSTM

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds VSTM. In Q2 2026, 1 added. Who we track

Torray Funds

Torray Funds · as of Q2 2026

$1.8M

477,455 shares

Moves in Q2 2026

Added: Torray Funds

About Verastem, Inc.

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works